Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer ...

Researchers have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

Iovance's Amtagvi is the first TIL therapy approved by the U.S. Food and Drug Administration (FDA). Its first approved indication is for advanced melanoma. Amtagvi is off to a great start after its ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance ...

Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.

The Sharks got to Fleury at the 12:11 mark of the first period, as William Eklund took a pass from Alexander Wennberg and fed ...

New research links multisystem inflammatory syndrome in children with COVID-19 to Epstein-Barr virus reactivation, revealing ...

Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.